Skip to main content
Erschienen in: Trials 1/2024

Open Access 01.12.2024 | Correction

Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

verfasst von: Simron Singh, Diego Ferone, Jaume Capdevila, Jennifer Ang Chan, Wouter W. de Herder, Daniel Halperin, Josh Mailman, Lisa Hellström, Hanna Liedman, Agneta Svedberg, Fredrik Tiberg

Erschienen in: Trials | Ausgabe 1/2024

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s13063-023-07834-8.
Correction: Trials 25, 58 (2024)
https://doi.org/10.1186/s13063-023-07834-8
Following publication of the original article [1], we have been notified that a correction is needed on page 3, paragraph 2 as shown below:
Incorrect statement: “Additionally, CAM2029 administration can be undertaken by the patient or carer themselves using a pre-filled pen, whereas administration of both octreotide LAR and lanreotide ATG requires medical assistance.”
Correct statement: “Additionally, CAM2029 administration can be undertaken by the patient or carer themselves using a pre-filled pen, whereas administration of octreotide LAR requires medical assistance. For patients who receive a stable dose of lanreotide ATG, the product can be administered either by the patient or by a trained person (Reference Somatuline Autogel 60 mg, solution for injection in a prefilled syringe—Summary of Product Characteristics (SmPC)—(emc) (medicines.org.uk)).”
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET
verfasst von
Simron Singh
Diego Ferone
Jaume Capdevila
Jennifer Ang Chan
Wouter W. de Herder
Daniel Halperin
Josh Mailman
Lisa Hellström
Hanna Liedman
Agneta Svedberg
Fredrik Tiberg
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
Trials / Ausgabe 1/2024
Elektronische ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-024-08146-1

Weitere Artikel der Ausgabe 1/2024

Trials 1/2024 Zur Ausgabe